FitProven
Evidence Breakdown
Based on 8 studies
THE BIGGER QUESTION
Whether this one statement holds is settled above. What to actually do about it is a wider question, weighed across every claim that bears on it.
Evidence map
For & against, at a glance
Animal Study
Pro
Staresinic M et al. · 2003Journal of Orthopaedic Research**Rat study**, not a human trial. Wistar rats had the right Achilles tendon surgically transected, then received intraperitoneal BPC-157 (10 µg, 10 ng or 10 pg/kg) or saline daily from 30 minutes post-surgery until autopsy. BPC-157-treated rats showed higher load to failure, higher Young's modulus of elasticity, better Achilles functional index scores, and superior fibroblast/collagen formation versus saline controls. This is one of the foundational tendon papers, from the Sikiric group in Zagreb that produced much of the BPC-157 literature; it supports the claim's *direction* but says nothing about humans.
0.11
**Rat study**, not a human trial. Wistar rats had the right Achilles tendon surgically transected, then received intraperitoneal BPC-157 (10 µg, 10 ng or 10 pg/kg) or saline daily from 30 minutes post-surgery until autopsy. BPC-157-treated rats showed higher load to failure, higher Young's modulus of elasticity, better Achilles functional index scores, and superior fibroblast/collagen formation versus saline controls. This is one of the foundational tendon papers, from the Sikiric group in Zagreb that produced much of the BPC-157 literature; it supports the claim's *direction* but says nothing about humans.
Design Animal Study (0.25) × quality 0.45 = impact 0.11
View sourceSystematic Review
Con
Vasireddi N et al. · 2025HSS JournalSystematic review of BPC-157 in orthopaedic sports medicine covering the literature from 1993 to 2024. Of 36 included studies, **35 were preclinical (animal models) and exactly one involved humans** — an uncontrolled retrospective series of 12 patients given intra-articular injections for chronic knee pain. The authors identified **no randomized controlled trials**, graded the entire body of evidence as Level IV–V, and concluded that BPC-157 should be considered investigational, warning that "adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety." This is the strongest available appraisal of the claim, and it finds the human evidence base effectively empty.
0.77
Systematic review of BPC-157 in orthopaedic sports medicine covering the literature from 1993 to 2024. Of 36 included studies, **35 were preclinical (animal models) and exactly one involved humans** — an uncontrolled retrospective series of 12 patients given intra-articular injections for chronic knee pain. The authors identified **no randomized controlled trials**, graded the entire body of evidence as Level IV–V, and concluded that BPC-157 should be considered investigational, warning that "adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety." This is the strongest available appraisal of the claim, and it finds the human evidence base effectively empty.
Design Systematic Review (0.9) × quality 0.85 = impact 0.77
View sourceNarrative Review
Con
McGuire FP et al. · 2025Current Reviews in Musculoskeletal MedicineNarrative/scoping review ("Regeneration or Risk?") searching six databases through March 2025 for BPC-157 in musculoskeletal healing. It found extensive rodent evidence but only **three published human studies** — intra-articular knee injection, bladder instillation, and an intravenous safety/pharmacokinetic study — **none of them randomized controlled trials**, concluding that "well-designed human trials are lacking." The review also reports the regulatory picture it found: WADA prohibited BPC-157 in 2022, and the FDA restricted its use in compounding in September 2023, citing safety, impurity and insufficient-human-data concerns.
0.15
Narrative/scoping review ("Regeneration or Risk?") searching six databases through March 2025 for BPC-157 in musculoskeletal healing. It found extensive rodent evidence but only **three published human studies** — intra-articular knee injection, bladder instillation, and an intravenous safety/pharmacokinetic study — **none of them randomized controlled trials**, concluding that "well-designed human trials are lacking." The review also reports the regulatory picture it found: WADA prohibited BPC-157 in 2022, and the FDA restricted its use in compounding in September 2023, citing safety, impurity and insufficient-human-data concerns.
Design Narrative Review (0.3) × quality 0.50 = impact 0.15
View sourceExpert Opinion
Con
U.S. Anti-Doping Agency · 2021USADA Athlete Advisory (2022 WADA Prohibited List)Official anti-doping advisory (published 13 October 2021) explaining that BPC-157, "the clinically unapproved experimental peptide," was **added to the 2022 WADA Prohibited List under category S0 (Non-Approved Substances)**, effective 1 January 2022 — the first time a substance was named explicitly as an example in S0. S0 covers substances not approved by any government health authority for human therapeutic use, and USADA notes that no Therapeutic Use Exemption can be granted for BPC-157 because it is not an approved therapeutic agent in any country. The advisory states BPC-157 lacks established safety data and has no proven efficacy for any medical condition — a direct regulatory contradiction of the marketed healing claim, though it is an agency position rather than experimental data.
0.14
Official anti-doping advisory (published 13 October 2021) explaining that BPC-157, "the clinically unapproved experimental peptide," was **added to the 2022 WADA Prohibited List under category S0 (Non-Approved Substances)**, effective 1 January 2022 — the first time a substance was named explicitly as an example in S0. S0 covers substances not approved by any government health authority for human therapeutic use, and USADA notes that no Therapeutic Use Exemption can be granted for BPC-157 because it is not an approved therapeutic agent in any country. The advisory states BPC-157 lacks established safety data and has no proven efficacy for any medical condition — a direct regulatory contradiction of the marketed healing claim, though it is an agency position rather than experimental data.
Design Expert Opinion (0.2) × quality 0.70 = impact 0.14
View sourceAnimal Study
Pro
Staresinic M et al. · 2003Journal of Orthopaedic Research**Rat study**, not a human trial. Wistar rats had the right Achilles tendon surgically transected, then received intraperitoneal BPC-157 (10 µg, 10 ng or 10 pg/kg) or saline daily from 30 minutes post-surgery until autopsy. BPC-157-treated rats showed higher load to failure, higher Young's modulus of elasticity, better Achilles functional index scores, and superior fibroblast/collagen formation versus saline controls. This is one of the foundational tendon papers, from the Sikiric group in Zagreb that produced much of the BPC-157 literature; it supports the claim's *direction* but says nothing about humans.
0.11
**Rat study**, not a human trial. Wistar rats had the right Achilles tendon surgically transected, then received intraperitoneal BPC-157 (10 µg, 10 ng or 10 pg/kg) or saline daily from 30 minutes post-surgery until autopsy. BPC-157-treated rats showed higher load to failure, higher Young's modulus of elasticity, better Achilles functional index scores, and superior fibroblast/collagen formation versus saline controls. This is one of the foundational tendon papers, from the Sikiric group in Zagreb that produced much of the BPC-157 literature; it supports the claim's *direction* but says nothing about humans.
Design Animal Study (0.25) × quality 0.45 = impact 0.11
View sourceSystematic Review
Con
Vasireddi N et al. · 2025HSS JournalSystematic review of BPC-157 in orthopaedic sports medicine covering the literature from 1993 to 2024. Of 36 included studies, **35 were preclinical (animal models) and exactly one involved humans** — an uncontrolled retrospective series of 12 patients given intra-articular injections for chronic knee pain. The authors identified **no randomized controlled trials**, graded the entire body of evidence as Level IV–V, and concluded that BPC-157 should be considered investigational, warning that "adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety." This is the strongest available appraisal of the claim, and it finds the human evidence base effectively empty.
0.77
Systematic review of BPC-157 in orthopaedic sports medicine covering the literature from 1993 to 2024. Of 36 included studies, **35 were preclinical (animal models) and exactly one involved humans** — an uncontrolled retrospective series of 12 patients given intra-articular injections for chronic knee pain. The authors identified **no randomized controlled trials**, graded the entire body of evidence as Level IV–V, and concluded that BPC-157 should be considered investigational, warning that "adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety." This is the strongest available appraisal of the claim, and it finds the human evidence base effectively empty.
Design Systematic Review (0.9) × quality 0.85 = impact 0.77
View sourceNarrative Review
Con
McGuire FP et al. · 2025Current Reviews in Musculoskeletal MedicineNarrative/scoping review ("Regeneration or Risk?") searching six databases through March 2025 for BPC-157 in musculoskeletal healing. It found extensive rodent evidence but only **three published human studies** — intra-articular knee injection, bladder instillation, and an intravenous safety/pharmacokinetic study — **none of them randomized controlled trials**, concluding that "well-designed human trials are lacking." The review also reports the regulatory picture it found: WADA prohibited BPC-157 in 2022, and the FDA restricted its use in compounding in September 2023, citing safety, impurity and insufficient-human-data concerns.
0.15
Narrative/scoping review ("Regeneration or Risk?") searching six databases through March 2025 for BPC-157 in musculoskeletal healing. It found extensive rodent evidence but only **three published human studies** — intra-articular knee injection, bladder instillation, and an intravenous safety/pharmacokinetic study — **none of them randomized controlled trials**, concluding that "well-designed human trials are lacking." The review also reports the regulatory picture it found: WADA prohibited BPC-157 in 2022, and the FDA restricted its use in compounding in September 2023, citing safety, impurity and insufficient-human-data concerns.
Design Narrative Review (0.3) × quality 0.50 = impact 0.15
View sourceExpert Opinion
Con
U.S. Anti-Doping Agency · 2021USADA Athlete Advisory (2022 WADA Prohibited List)Official anti-doping advisory (published 13 October 2021) explaining that BPC-157, "the clinically unapproved experimental peptide," was **added to the 2022 WADA Prohibited List under category S0 (Non-Approved Substances)**, effective 1 January 2022 — the first time a substance was named explicitly as an example in S0. S0 covers substances not approved by any government health authority for human therapeutic use, and USADA notes that no Therapeutic Use Exemption can be granted for BPC-157 because it is not an approved therapeutic agent in any country. The advisory states BPC-157 lacks established safety data and has no proven efficacy for any medical condition — a direct regulatory contradiction of the marketed healing claim, though it is an agency position rather than experimental data.
0.14
Official anti-doping advisory (published 13 October 2021) explaining that BPC-157, "the clinically unapproved experimental peptide," was **added to the 2022 WADA Prohibited List under category S0 (Non-Approved Substances)**, effective 1 January 2022 — the first time a substance was named explicitly as an example in S0. S0 covers substances not approved by any government health authority for human therapeutic use, and USADA notes that no Therapeutic Use Exemption can be granted for BPC-157 because it is not an approved therapeutic agent in any country. The advisory states BPC-157 lacks established safety data and has no proven efficacy for any medical condition — a direct regulatory contradiction of the marketed healing claim, though it is an agency position rather than experimental data.
Design Expert Opinion (0.2) × quality 0.70 = impact 0.14
View sourceShowing the 4 strongest of 8 studies. Tap any node to expand its detail.
Evidence
PRO (3)
PRO Animal Study0.45 Staresinic M, Sebecic B et al. (2003)
Intraperitoneal BPC-157 (10 ug, 10 ng or 10 pg/kg) improved load to failure, Young's modulus, Achilles functional index and fibroblast/collagen formation versus saline after surgical Achilles transection
Rat study, not a human trial. Wistar rats had the right Achilles tendon surgically transected, then received intraperitoneal BPC-157 (10 µg, 10 ng or 10 pg/kg) or saline daily from 30 minutes post-surgery until autopsy. BPC-157-treated rats showed higher load to failure, higher Young's modulus of elasticity, better Achilles functional index scores, and superior fibroblast/collagen formation versus saline controls. This is one of the foundational tendon papers, from the Sikiric group in Zagreb that produced much of the BPC-157 literature; it supports the claim's direction but says nothing about humans.
Weighted 0.45 — Wistar rats; the exact number of animals and per-group allocation could not be confirmed (full text paywalled), so sample_size is omitted rather than guessed, as is funding. Objective biomechanical and histological endpoints and a dose range are strengths. The independence concern is real and specific: the BPC-157 literature is dominated by the single Zagreb group (Sikiric et al.) associated with the peptide's development, and no independent replication exists; randomisation and blinding are not documented. Mid-range within the animal class, and it says nothing about humans.
Journal of Orthopaedic Research
PRO Animal Study0.35 Chang CH, Tsai WC et al. (2011)
BPC-157 accelerated fibroblast outgrowth from tendon explants, improved fibroblast survival under oxidative stress and dose-dependently increased cell migration via FAK-paxillin activation; it did NOT increase fibroblast proliferation
Rat study with in vitro work, not a human trial — and notably from an independent Taiwanese group rather than the Zagreb lab. Using transected rat Achilles tendon and cultured rat tendon fibroblasts, BPC-157 accelerated outgrowth from tendon explants, improved fibroblast survival under oxidative stress, and dose-dependently increased cell migration; it did not increase fibroblast proliferation. The authors attribute the effect to FAK-paxillin pathway activation. It is mechanistic support for a plausible healing effect, in rodent tissue only.
Weighted 0.35 — Male Sprague-Dawley rats — the number of animals is not stated in any accessible version of the paper, so sample size is omitted rather than guessed, and the work is predominantly ex vivo (tendon explant culture and isolated fibroblasts) rather than a whole-animal healing trial. The paper is paywalled with no retrievable funding statement. It earns the upper end of the animal/mechanistic band only because it comes from an independent Taiwanese group rather than the lab that originated BPC-157. Severe indirectness for any human claim.
Journal of Applied Physiology
PRO Animal Study0.20 Krivic A, Anic T et al. (2006)
BPC-157 increased load to failure, stiffness and Young's elasticity modulus at the tendon-to-bone junction, improved functional recovery, produced better-organised collagen with more type I collagen, and blunted the healing impairment caused by 6-alpha-methylprednisolone
Rat study, not a human trial. Wistar rats had the Achilles tendon sharply detached from the calcaneus; BPC-157 treatment significantly increased load to failure, stiffness and Young's elasticity modulus, improved functional recovery, and produced better-organized collagen fibres and more type I collagen than controls. BPC-157 also blunted the healing impairment caused by 6α-methylprednisolone. Same Zagreb research group as the other foundational tendon work, which limits how much independent replication this represents.
Weighted 0.20 — Rat study (male Wistar albino, 280-300 g). The paper reports 12 rats per group per time point across 6 groups and 6 time points but NEVER states a total n, so none is recorded here rather than inferred by arithmetic. Enormous indirectness to human tendon healing. It carries no conflict-of-interest statement despite the senior author being the originator and patent-holder of BPC-157 and the peptide being supplied by a commercial manufacturer; essentially all foundational BPC-157 work comes from this single Zagreb lab, so it is effectively unreplicated externally.
Funding: Ministry of Science, Technology and Sports of the Republic of Croatia (grant 108196)
Journal of Orthopaedic Research
AGAINST (3)
AGAINST Systematic Review0.85 Vasireddi N, Hahamyan H et al. (2025)
36 studies: 35 preclinical animal studies and exactly one human study (an uncontrolled retrospective series of 12 patients). Zero RCTs; entire body of evidence graded Level IV-V
Systematic review of BPC-157 in orthopaedic sports medicine covering the literature from 1993 to 2024. Of 36 included studies, 35 were preclinical (animal models) and exactly one involved humans — an uncontrolled retrospective series of 12 patients given intra-articular injections for chronic knee pain. The authors identified no randomized controlled trials, graded the entire body of evidence as Level IV–V, and concluded that BPC-157 should be considered investigational, warning that "adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety." This is the strongest available appraisal of the claim, and it finds the human evidence base effectively empty.
Weighted 0.85 — k=36 studies with no pooled human sample — only 12 humans exist in this entire literature, which is itself the finding. Current (1993-2024), directly on point, and its conclusion is robust precisely because it is a claim about absence. Co-authors disclose orthopaedic device relationships (Stryker, Smith & Nephew, Arthrex, Mitek), none of them a BPC-157 vendor, so the commercial ties are adjacent rather than direct. No funding statement is retrievable.
HSS Journal
AGAINST Expert Opinion0.70 U.S. Anti-Doping Agency (2021)
BPC-157 added to the 2022 WADA Prohibited List under category S0 (non-approved substances), effective 1 January 2022; no Therapeutic Use Exemption possible
Official anti-doping advisory (published 13 October 2021) explaining that BPC-157, "the clinically unapproved experimental peptide," was added to the 2022 WADA Prohibited List under category S0 (Non-Approved Substances), effective 1 January 2022 — the first time a substance was named explicitly as an example in S0. S0 covers substances not approved by any government health authority for human therapeutic use, and USADA notes that no Therapeutic Use Exemption can be granted for BPC-157 because it is not an approved therapeutic agent in any country. The advisory states BPC-157 lacks established safety data and has no proven efficacy for any medical condition — a direct regulatory contradiction of the marketed healing claim, though it is an agency position rather than experimental data.
Weighted 0.70 — Regulatory position statement, not experimental data, so no sample size applies. Authoritative, independent of any commercial interest and directly decisive on the regulatory status of BPC-157 — a strong instance of its class — but it presents no efficacy or safety data of its own, so it cannot settle the underlying biological claim.
USADA Athlete Advisory (2022 WADA Prohibited List)
https://www.usada.org/athlete-advisory/key-changes-2022-prohibited-list/
AGAINST Narrative Review0.50 McGuire FP, Martinez R et al. (2025)
extensive rodent evidence but only three published human studies, none of them randomized controlled trials; WADA prohibited BPC-157 in 2022 and the FDA restricted its use in compounding in September 2023
Narrative/scoping review ("Regeneration or Risk?") searching six databases through March 2025 for BPC-157 in musculoskeletal healing. It found extensive rodent evidence but only three published human studies — intra-articular knee injection, bladder instillation, and an intravenous safety/pharmacokinetic study — none of them randomized controlled trials, concluding that "well-designed human trials are lacking." The review also reports the regulatory picture it found: WADA prohibited BPC-157 in 2022, and the FDA restricted its use in compounding in September 2023, citing safety, impurity and insufficient-human-data concerns.
Weighted 0.50 — A narrative/scoping review, so there is no pooled sample — but it is a competent and fully independent one, searching six databases through March 2025 with no funding and no conflicts declared. Its central claim is an absence claim (well-designed human trials are lacking), which a thorough search is well suited to establish, and the regulatory actions it reports are matters of public record. Weighted above a typical narrative review for that reason, while the underlying human literature amounts to three uncontrolled studies.
Funding: none declared
Current Reviews in Musculoskeletal Medicine
NEUTRAL (2)
NEUTRAL Expert Opinion0.35 U.S. Food and Drug Administration (2026)
BPC-157 is not an FDA-approved drug; under review as an unapproved bulk substance, evaluated only for ulcerative colitis
FDA notice (published 16 April 2026) announcing that the Pharmacy Compounding Advisory Committee will meet on 23 July 2026 to discuss whether BPC-157-related bulk drug substances (free base and acetate) should be added to the Section 503A Bulks List. It confirms BPC-157 is not an FDA-approved drug and remains an unapproved bulk substance under review; notably, the only use FDA evaluated for BPC-157 in this review is ulcerative colitis — not tendon, muscle or any musculoskeletal indication. No final determination had been issued at the time of the notice, so this establishes regulatory context rather than evidence for or against the healing claim.
Weighted 0.35 — A regulatory notice, not a study: no participants and no outcome data. It carries weight as authoritative regulatory context, but it is seriously indirect for the tendon and muscle healing claim - the only indication FDA evaluated was ulcerative colitis, and no final determination had been issued.
Federal Register (Docket No. FDA-2025-N-6895)
NEUTRAL Case Studyn=160.15 Lee E, Padgett B (2021)
14 of 16 patients (87.5%) reported that their knee pain had improved when telephoned 6-12 months after intra-articular BPC-157 injection
This is the only published human musculoskeletal study of BPC-157, and it is an uncontrolled retrospective chart review at a private hormone clinic: 16 paying patients who had received intra-articular knee injections of BPC-157 (n=12) or BPC-157 plus thymosin-beta-4 (n=4) were phoned 6–12 months later and asked whether their knee pain had improved; 14 of 16 (87.5%) said yes. There was no control group, no placebo, no blinding, no imaging and no objective function endpoint — the authors concede "no specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living." It measures self-reported pain, not tissue healing, and cannot distinguish drug effect from placebo or natural history, so it neither supports nor refutes the claim that BPC-157 accelerates healing.
Weighted 0.15 — n=16 analysed (17 injected, 1 unreachable) in an uncontrolled retrospective chart review at a single private hormone clinic. No control, no placebo, no blinding, no imaging for 12 of the 16, and the sole endpoint is self-reported pain gathered by telephone by a student volunteer. Written in the first person by the treating physician who sold the procedure -- a structural conflict the paper's no-conflicts declaration does not capture -- and no funding statement exists. It cannot separate drug effect from placebo or natural history, so it neither supports nor refutes the claim, despite being the only published human musculoskeletal study of BPC-157.
Alternative Therapies in Health and Medicine